EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders

View source ↗

Summary

The EMA confirms risk-minimising measures for Janus kinase inhibitors used in chronic inflammatory disorders to address serious side effects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Disorders